Company / Cash & Equivalents
Amneal Pharmaceuticals, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$282.0M
FY2025
5-year range
$26.0M / $341.4M
FY2021-FY2025
Trend
+155.1%
vs FY2024
Sector context
#67 of 207
Health Care
What the data says
At $282M, Amneal Pharmaceuticals, Inc.'s cash & equivalents ranks #67 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $26M in FY2023 to $341M in FY2021.
Based on SEC 10-K filings.
$282M in FY2025 with a 5-year CAGR of +13.3%.
Improved from $26M to $282M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +121.4%
- 5-Year CAGR
- +13.3%
- 10-Year CAGR
- -
Sector benchmark
#67 of 207 in Health CareTop 32% of 207This company $282.0M Sector average $669.5M
▼
-57.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 155.1% year-over-year.
- Ranks #67 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $282.0M | +155.1% |
| FY2024 | $110.6M | +325.6% |
| FY2023 | $26.0M | +0.0% |
| FY2022 | $26.0M | -92.4% |
| FY2021 | $341.4M | +125.8% |
| FY2020 | $151.2M | -29.1% |
| FY2019 | $213.4M | +187.7% |
| FY2018 | $74.2M | +0.0% |
| FY2017 | $74.2M | +171.0% |
| FY2016 | $27.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026